Celldex’s Phase 1b Study on Barzolvolimab for Prurigo Nodularis to be Presented at 12th World Congress on Itch 2023 in Miami

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.

Presentation details are below:

Abstract Title: Barzolvolimab demonstrates safety and clinically meaningful activity in moderate-severe prurigo nodularis

Presenting Author: Martin Metz, M.D., Professor of Dermatology and Allergy at Charité – Universitätsmedizin in Berlin

Session: Hot Topics

Date/Time: Tuesday, November 7 at 3:20 PM – 3:28 PM ET

The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimab in patients with prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.

Total
0
Shares
Related Posts
Read More

Sports Betting Legislator Ryan Butler Tweets ‘Entertainment (Formerly Penn National) Could Continue Rebranding With New Moves Like Renaming Its Hollywood Casinos As “Hollywood Casino By Penn”, Ceo Jay Snowden Said During Today’s G2E Conference’

(1) Ryan Butler on Twitter: "$PENN Entertainment (formerly Penn National) could continue rebranding with new moves like renaming its Hollywood casinos as "Hollywood Casino by Penn", CEO Jay Snowden said

PENN